Plerixafor for Autologous Stem-Cell Mobilization and Transplantation for Patients in Ontario

Kouroukis, C. Tom; Varela, Norma P.; Bredeson, Chris; Kuruvilla, John; Xenocostas, Anargyros

doi:10.3747/co.23.3137

Cited by 17 publications

(14 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second‐time mobilization is a technique that has been used successfully to collect enough stem cells for ASCT 5,6,9,11‐21 . However, we were not able to find any reports on third‐time mobilization.…”

Section: Discussionmentioning

confidence: 87%

Third time’s a charm? Mobilization of autologous peripheral blood stem cells in patients with two previous failed mobilizations with plerixafor

et al. 2020

View full text Add to dashboard Cite

BACKGROUND Patients who respond inadequately to plerixafor salvage during autologous peripheral blood stem cell (PBSC) collection are frequently remobilized with plerixafor to collect additional stem cells. However, in patients who fail remobilization, it is unclear whether additional mobilization efforts with plerixafor are useful. STUDY DESIGN AND METHODS We retrospectively examined the PBSC collections of 15 consecutive patients with lymphoma and multiple myeloma who underwent three mobilizations with plerixafor. RESULTS Of the 821 patients who underwent autologous stem cell collections, 15 patients were mobilized three times with plerixafor (1.8%), which enabled 11 (73.3%) patients to reach 2.0 × 106 CD34+ cells/kg or greater. Among patients who eventually collected successfully the median yields from the three collection attempts were 0.46, 0.76, and 1.54 × 106 CD34+ cells/kg, respectively. Among those who collected less than 2.0 × 106 CD34+ cells/kg cumulatively, the median yields were 0.14, 0.33, and 0.22 × 106 CD34+ cells/kg from the three collection attempts. The combined collection yields from the first two mobilization attempts were significantly lower (p = 0.003; range, 0.09‐0.73 vs. 0.63‐1.84; median, 0.51 vs. 1.36) in those who failed collection. CONCLUSIONS The majority (73.3%) of patients who underwent three mobilization attempts were eventually able to collect enough cells to permit autologous transplantation. Extremely low peripheral blood CD34+ count after the first dose of plerixafor and collection yields during the first two attempts were associated with a poor collection yield on the third attempt. The risks and benefits of a third mobilization should be weighed to facilitate judicious use of resources.

show abstract

Section: Discussionmentioning

confidence: 87%

Third time’s a charm? Mobilization of autologous peripheral blood stem cells in patients with two previous failed mobilizations with plerixafor

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Alternatively, the Cancer Care Ontario practice guidelines outline specific criteria indicating when plerixafor is recommended as an add-on treatment to G-CSF in mobilizing and harvesting stem cells before autologous stem cell transplant. 13 The reported failure rate of stem cell mobilization has been quite high, in global terms, with the number of patients experiencing failure estimated in the range of 5000 to 10 000 annually. 4 Mobilization failure rates were documented as high with the use of G-CSF and chemotherapy, with an estimated range from 5% to 30% in both allogeneic and autologous stem cell transplantation.…”

Section: Discussionmentioning

confidence: 99%

Chemical Stability of Plerixafor after Opening of Single-Use Vial

Seki

Božović

Lee

et al. 2017

CJHP

View full text Add to dashboard Cite

Background: The addition of the immunostimulant plerixafor to the current standard-of-care regimens of granulocyte colony-stimulating growth factor with or without chemotherapy has improved clinical results in terms of successful stem cell mobilization and the outcomes of stem cell transplant in various settings. With this medical innovation has come an added financial cost for institutions where stem cell transplants are routinely performed, and there may be a further financial burden when the contents of partial vials of the drug are wasted, given that plerixafor vials (Mozobil, Sanofi-Aventis Canada Inc) are currently deemed suitable only for single use.

show abstract

“…12 Stem cell mobilization is more efficient with plerixafor, 15 which is indicated in association with G-CSF for the mobilization of hematopoietic stem cells into the peripheral blood. 16,17 In the Clinic of Hematology and Bone Marrow Transplantation of Tîrgu Mureș, Romania, a study on poor mobilizers patients is in progress. The study is not specifically for patients with multiple myeloma, but the partial results are significantly satisfying.…”

Section: The Present In Multiple Myeloma Treatmentmentioning

confidence: 99%

New Treatment Methods in Multiple Myeloma

Jakab

Lázár

Köpeczi³

et al. 2017

Journal of Interdisciplinary Medicine

View full text Add to dashboard Cite

Multiple myeloma accounts for 10% of the hematologic malignancies and is characterized by a single clone of plasma cells producing a monoclonal protein. The aim of this review is to summarize the current treatment methods of multiple myeloma. In the last 15 years, the incidence of myeloma has increased in patients younger than 65 years, thus treatment became even more important in order to obtain a long lasting remission or plateau phase. The treatment of this disease is complex and focuses not only on increasing the patients’ survival, but also improving their quality of life.

show abstract

Plerixafor for Autologous Stem-Cell Mobilization and Transplantation for Patients in Ontario

Abstract: Background High-dose chemotherapy with autologous stem-cell transplantation (asct) is an accepted part of

Cited by 17 publications

References 29 publications

Third time’s a charm? Mobilization of autologous peripheral blood stem cells in patients with two previous failed mobilizations with plerixafor

Third time’s a charm? Mobilization of autologous peripheral blood stem cells in patients with two previous failed mobilizations with plerixafor

Chemical Stability of Plerixafor after Opening of Single-Use Vial

New Treatment Methods in Multiple Myeloma

Contact Info

Product

Resources

About